Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
US Supreme Court Reignites Claims Government Overcharged Millions For Generics
In a case that could have significant ramifications for the scope of the US False Claims Act, the US Supreme Court has agreed to remand for further proceedings allegations that supermarket and pharmacy chains defrauded the government via low-cost drug programs.
Coherus Plots ‘Lowest Price Adalimumab’ With Huge Discount, Ties Up With Mark Cuban
Coherus BioSciences had teased a “compelling value proposition” for its Yusimry (adalimumab-aqvh) biosimilar to AbbVie’s Humira blockbuster and it has delivered, with a pair of pricing strategies include one though an alliance with self-labelled “disruptor” Mark Cuban.
Ivabradine Prices Rise High Among Recent UK Launches In April
Ivabradine stood out among recently-launched UK generics with an average price rise of more than a third in April, according to the latest figures from market researcher WaveData.
Samsung Bioepis Biosimilars Report Sees Lower Price Boosting Uptake
Samsung Bioepis has published the first in a planned series of reports on the US biosimilars market, including insights into pricing, uptake and market share for various biosimilars.
PBM Vertical Integration Impact Under The Microscope At Senate Hearing
A US Senate Finance Committee has heard divided opinions on the impact of vertical integration among pharmacy benefit managers, with one witness maintaining it may have positive competitive consequences while another condemned the practice outright.
UK Generics Body Opens Rift With Government And Originators Over Rebate Scheme
By launching a bid for judicial review of its exclusion from UK negotiations over the VPAS rebate scheme, the BGMA has thrust itself into conflict with the country’s government as well as local brand industry association the ABPI.
PBM Impact On Off-Patent Industry Condemned At Senate Hearing
Witnesses at a US Senate Finance Committee Hearing have condemned the impact the “perverse” practices of pharmacy benefit managers have on off-patent drugs, often placing them on non-preferred tiers so that patients must use more expensive, branded medication.
Express Scripts Unveils New Co-Pay Cap For Generics Amid PBM Scrutiny
Cigna’s PBM, Express Scripts, is looking to “further align incentives across the pharmaceutical supply chain, consumers, and clients,” with a trio of new products available starting this summer.
Perindopril And Pramipexole Prices Peak In March
Two products featured highly among the fastest-rising UK generics prices in March, but for different reasons.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.